Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East

Seminars in Liver Disease

Volumn 23, Issue 3, 2003, Pages 239-250

  Cheng, Vincent C C ^b   Lo, Chung Mau ^b   Lau, George K K ^a,b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Far East; Fulminant hepatic failure; Hepatitis B infection; Liver transplantation

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIBIOTIC AGENT; BENZBROMARONE; CARBIMAZOLE; CLARITHROMYCIN; CLOZAPINE; CYPROTERONE ACETATE; DAPSONE; DIDANOSINE; DISULFIRAM; ETHAMBUTOL; HEPATITIS B SURFACE ANTIGEN; ISONIAZID; LAMIVUDINE; METHYLDOPA; NEVIRAPINE; NIPEROTIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPYLTHIOURACIL; PROTON PUMP INHIBITOR; PYRAZINAMIDE; QUINIDINE; RABEPRAZOLE; RIFAMPICIN; TOLCAPONE; TROGLITAZONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALPROIC ACID;

DISEASE EXACERBATION; ENDEMIC DISEASE; FAR EAST; HEPATITIS B; HONG KONG; HUMAN; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; PRIORITY JOURNAL; REVIEW; SURVIVAL; VIRUS HEPATITIS;

FAR EAST; HEPATITIS B; HONG KONG; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LAMIVUDINE; LIVER FAILURE; LIVER TRANSPLANTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0042820260     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42642     Document Type: Review

References (152)

1. Ostapowicz G, Lee WM. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol 2000;15:480-488
2. Bowen DG, Shackel NA, McCaughan GW. East meets West: acute liver failure in the global village. J Gastroenterol Hepatol 2000;15:467-469
3. Lau GK. Hepatitis B infection in China. Clinics in Liver Disease 2001;5:361-379
4. Acharya SK, Dasarathy S, Kumer TL, et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996;23:1448-1455
5. Meyer RA, Duffy MC. Spontaneous reactivation of chronic hepatitis B infection leading to fulminant hepatic failure. Report of two cases and review of the literature. J Clin Gastroenterol 1993;17:231-234
6. Xunrong L, Yan AW, Liang R, Lau GKK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy - pathogenesis and management. Reviews in Medical Virology 2001;11:1-14
7. Leifeld L, Cheng S, Ramakers J, et al. Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology 2002;36:1001-1008
8. Makuuchi M, Kawarazaki H, Iwanaka T, et al. Living related liver transplantation. Surg Today 1992;22:297-300
9. Yamaoka Y, Washida M, Honda K, et al. Liver transplantation using a right lobe graft from a living related donor. Transplantation 1994;57:1127-1130
10. Lo CM, Chan KL, Fan ST, et al. Living donor liver transplantation: the Hong Kong experience. Transplant Proc 1996;28:2390-2392
11. Chan TY. Fulminant hepatic failure due to acetaminophen poisoning may be less common in Hong Kong. J Toxicol Clin Toxicol 2001;39:175-177
12. Fan ST, Lo CM, Lo RJ, et al. Management of fulminant hepatic failure at Queen Mary Hospital. Chin Med J (Engl) 1997;110:482-484
13. Ostapowicz G, Fontana RJ, Schiodt FV, et al. U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002 17;137:947-954
14. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996;22:211-214
15. Chu CM, Liaw YF. The incidence of fulminant hepatic failure in acute viral hepatitis in Taiwan: increased risk in patients with pre-existing HBsAg carrier state. Infection 1990;18:200-203
16. Takahashi Y, Shimizu M. Aetiology and prognosis of fulminant viral hepatitis in Japan: a multicentre study. The Study Group of Fulminant Hepatitis. J Gastroenterol Hepatol 1991;6:159-164
17. Chu CM, Liaw YF. The incidence of fulminant hepatic failure in acute viral hepatitis in Taiwan: increased risk in patients with pre-existing HBsAg carrier state. Infection 1990;18:200-203
18. Fujiwara K, Mochida S. Indications and criteria for liver transplantation for fulminant hepatic failure. J Gastroenterol 2002;37(Suppl 13):74-77
19. Kao JH, Hsu HM, Shau WY, et al. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001;139:349-352
20. Lau GK, Williams R. HCV in hepatic failure: West and East do not meet. Gut 1999;45:481-482
21. Wright TL, Mamish D, Combs C, et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet 1992;339:952-955
22. Liang TJ, Jeffers L, Reddy RK, et al. Fulminant of subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses. Gastroenterology 1993;104:556-562
23. Feray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993;104:549-555
24. Sallie R, Silva AE, Purdy M, et al. Hepatitis C and E in non-A non-B fulminant hepatic failure: a polymerase chain reaction and serological study. J Hepatol 1994;20:580-588
25. Muto Y, Sugihara J, Ohnishi H, et al. Anti-hepatitis C virus antibody prevails in fulminant hepatic failure. Gastroenterol Jpn 1990;25:32-35
26. Yanagi M, Kaneko S, Unoura M, et al. Hepatitis C virus in fulminant hepatic failure. N Engl J Med 1991;324:1895-1896
27. Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology 1994;107:189-195
28. Wu JC, Chen CL, Hou MC, et al. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: Application and limitations of the polymerase chain reaction. Hepatology 1994;19:836-840
29. Zhao YR, Zhang DF, Pan CQ. An etiological study on fulminant viral hepatitis. Chin J Int Med 1992;31:686-688
30. Liaw YF, Tsai SL, Chang JJ, et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994;106:1048-1053
31. Lau GKK, Wu PC, Lo CK, et al. Histological changes of concurrent hepatitis C virus infection in asymptomatic hepatitis B virus patients. J Gastroenterol Hepatol 1998;13:52-56
32. Masada CT, Shaw BW Jr, Zetterman RK, et al. Fulminant hepatic failure with massive necrosis as a result of hepatitis A infection. J Clin Gastroenterol 1993;17:158-162
33. Coursaget P, Buisson Y, N'Gawara MN, et al. Role of hepatitis E virus in sporadic cases of acute and fulminant hepatitis in an endemic area (Chad). Am J Trop Med Hyg 1998;58:330-334
34. Nanda SK, Yalcinkaya K, Panigrahi AK, et al. Etiological role of hepatitis E virus in sporadic fulminant hepatitis. J Med Virol 1994;42:133-137
35. Lau JY, Sallie R, Fang JW, et al. Detection of hepatitis E virus genome and gene products in two patients with fulminant hepatitis E. J Hepatol 1995;22:605-610
36. Liang TJ, Jeffers L, Reddy RK, et al. Fulminant or subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses. Gastroenterology 1993;104:556-562
37. Lee WS, Kelly DA, Tanner MS, et al. Neonatal liver transplantation for fulminant hepatitis caused by herpes simplex virus type 2. J Pediatr Gastroenterol Nutr 2002;35:220-223
38. Pinna AD, Rakela J, Demetris AJ, Fung JJ. Five cases of fulminant hepatitis due to herpes simplex virus in adults. Dig Dis Sci 2002;47:750-754
39. Farr RW, Short S, Weissman D. Fulminant hepatitis during herpes simplex virus infection in apparently immunocompetent adults: report of two cases and review of the literature. Clin Infect Dis 1997;24:1191-1194
40. Asano Y, Yoshikawa T, Suga S, et al. Fatal fulminant hepatitis in an infant with human herpesvirus-6 infection. Lancet 1990;335:862-863
41. Sokal EM, Melchior M, Cornu C, et al. Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet 1998;352:1739-1741
42. Masia M, Gutierrez F, Jimeno A, et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch Intern Med 2002;162:474-476
43. Chalasani P, Baffoe-Bonnie H, Jurado RL. Dapsone therapy causing sulfone syndrome and lethal hepatic failure in an HIV-infected patient. South Med J 1994;87:1145-1146
44. Bourliere M, Bernuau J, Rueff B, Benhamou JP. Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman. A case report. J Hepatol 1988;6:214-216
45. van Aalderen WM, Knoester H, Knol K. Fulminant hepatitis during treatment with rifampicin, pyrazinamid and ethambutol. Eur J Pediatr 1987;146:290-291
46. Bartelink AK, Lenders JW, van Herwaarden CL, et al. Fatal hepatitis after treatment with isoniazid and rifampicin in a patient on anticonvulsant therapy. Tubercle 1983;64:125-128
47. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001;49:1153-1156
48. Lacaille F, Ortigao MB, Debre M, et al. Hepatic toxicity associated with 2'-3' dideoxyinosine in children with AIDS. J Pediatr Gastroenterol Nutr 1995;20:287-290
49. Breuer HW, Bossek W, Haferland C, et al. Amiodarone-induced severe hepatitis mediated by immunological mechanisms. Int J Clin Pharmacol Ther 1998;36:350-352
50. Seggie J, Saunders SJ, Kirsch RE, et al. Patterns of hepatic injury induced by methyldopa. S Afr Med J 1979;55:75-83
51. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet 1998;352:958
52. Macfarlane B, Davies S, Mannan K, et al. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997;112:1707-1709
53. Colletti RB, Trainer TD, Krawisz BR. Reversible valproate fulminant hepatic failure. J Pediatr Gastroenterol Nutr 1986;5:990-994
54. Danan G, Bernuau J, Moullot X, et al. Amitriptyline-induced fulminant hepatitis. Digestion 1984;30:179-184
55. Johnstone D, Berger C, Fleckman P. Acute fulminant hepatitis after treatment with rabeprazole and terbinafine. Arch Intern Med 2001;161:1677-1678
56. Andrade RJ, Lucena MI. Acute fulminant hepatitis after treatment with rabeprazole and terbinafine: is rabeprazole the culprit? Arch Intern Med 2002;162:360-361
57. Gasbarrini G, Gentiloni N, Febbraro S, et al. Acute liver injury related to the use of niperotidine. J Hepatol 1997;27:583-586
58. Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol 2000;32:874
59. Shibuya A, Watanabe M, Fujita Y, et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998;21:2140-2143
60. Deidiker R, deMello DE. Propylthiouracil-induced fulminant hepatitis: case report and review of the literature. Pediatr Pathol Lab Med 1996;16:845-852
61. Mihas AA, Holley P, Koff RS, Hirschowitz BI. Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 1976;70:770-774
62. Epeirier JM, Pageaux GP, Coste V, et al. Fulminant hepatitis after carbimazole and propranolol administration. Eur J Gastroenterol Hepatol 1996;8:287-288
63. Friedman G, Lamoureux E, Sherker AH. Fatal fulminant hepatic failure due to cyproterone acetate. Dig Dis Sci 1999;44:1362-1363
64. Ohana M, Hajiro K, Takakuwa H, Okazaki K. Recovery from diclofenac-induced hypersensitive fulminant hepatitis and prostaglandins. Dig Dis Sci 1997;42:2031-2032
65. Danan G, Trunet P, Bernuau J, et al. Pirprofen-induced fulminant hepatitis. Gastroenterology 1985;89:210-213
66. Purdum PP 3rd, Shelden SL, Boyd JW, Shiffman ML. Oxaprozin-induced fulminant hepatitis. Ann Pharmacother 1994;28:1159-1161
67. Gordon DW, Rosenthal G, Hart J, et al. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA 1995;273:489-490
68. Mattei A, Rucay P, Samuel D, et al. Liver transplantation for severe acute liver failure after herbal medicine (Teucrium polium) administration. J Hepatol 1995;22:597
69. Bakerink JA, Gospe SM Jr, Dimand RJ, Eldridge MW. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics 1996;98:944-947
70. Hullar TE, Sapers BL, Ridker PM, et al. Herbal toxicity and fatal hepatic failure. Am J Med 1999;106:267-268
71. Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002;177:440-443
72. Mels GC, Bellati G, Leandro G, et al. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. Liver 1994;14:175-181
73. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120:1009-1022
74. Lau GK, Wang B, Carman W. Immunological approaches to the breakdown of hepatitis B viral persistence. Chin Med J (Engl) 1998;111:560-564
75. Perrillo RP, Campbell CR, Sanders GE, et al. Spontaneous clearance and reactivation of hepatitis B virus infection among male homosexuals with chronic type B hepatitis. Ann Intern Med 1984;100:43-46
76. Hoofnagle JH, Seeff LB. Natural history of chronic type B hepatitis. Prog Liver Dis 1982;7:469-479
77. Carman WF, Fagan EA, Hadziyannis S, et al. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991;14:219-222
78. Ehata T, Omata M, Chuang WL, et al. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest 1993;91:1206-1213
79. Kaneko M, Uchida T, Moriyama M, et al. Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B. J Med Virol 1995;47:204-208
80. Sato S, Suzuki K, Akahane Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995;122:241-248
81. Friedt M, Gerner P, Lausch E, et al. Mutations in the basic core promotor and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology 1999;29:1252-1258
82. Pollicino T, Zanetti AR, Cacciola I, et al. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology 1997;26:495-499
83. Sterneck M, Kalinina T, Gunther S, et al. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology 1998;28:1390-1397
84. Omata M, Ehata T, Yokosuka O, et al. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991;324:1699-1704
85. Kosaka Y, Takase K, Kojima M, et al. Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991;100:1087-1094
86. Liang TJ, Hasegawa K, Rimon N, et al. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-1709
87. Hsu HY, Chang MH, Lee CY, et al. Precore mutant of hepatitis B virus in childhood fulminant hepatitis B: an infrequent association. J Infect Dis 1995;171:776-781
88. Feray C, Gigou M, Samuel D, et al. Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis B in France. J Hepatol 1993;18:119-122
89. Laskus T, Persing DH, Nowicki MJ, et al. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. Gastroenterology 1993;105:1173-1178
90. Brunetto MR, Giarin MM, Oliveri F, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 1991;88:4186-4190
91. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31:1037-1044
92. Inoue K, Yoshiba M, Sekiyama K, et al. Clinical and molecular virological differences between fulminant hepatic failures following acute and chronic infection with hepatitis B virus. J Med Virol 1998;55:35-41
93. Lok AS, Heatgcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastreoenterelogy 2001;120:1828-1853
94. Ayres A, Bartholomeusz A, Lau GK, et al. Lamivudine and famciclovir resistant hepatitis B virus with mutations in basal core promoter and X protein associated with severe and fatal liver disease. J Clin Virol 2003;27:111-116
95. Bonacini M, Kurz A, Locarnini S, et al. Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002;122:244-245
96. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-709
97. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev Immunol 1995;13:29
98. Kimura K, Ando K, Tomita E, et al. Elevated intracellular IFN-gamma levels in circulating CD8+ lymphocytes in patients with fulminant hepatitis. J Hepatol 1999;31:579-583
99. Suzuki K, Endo R, Nakamura N, et al. Serum level of soluble Fas ligand in patients with acute and fulminant hepatitis: relationship with soluble Fas, tumor necorsis factor α and TNF receptor I. Hepatol Res 2000;17:19-30
100. Nagaki M, Iwai H, Naiki T, et al. High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitis. J Infect Dis 2000;182:1103-1108
101. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Nalt Acad Sci USA 1986;83:1627-1631
102. Cheng VC, Yuen KY, Wong SS, et al. Immunorestitution diseases in patients not infected with HIV. Eur J Clin Microbiol Infect Dis 2001;20:402-406
103. McIvor C, Morton J, Bryant A, et al. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med 1994;121:274-275
104. Caselitz M, Link H, Hein R, et al. Hepatitis B associated liver failure following bone marrow transplantation. J Hepatol 1997;27:572-577
105. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2:528-530
106. Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985;145:1313-1314
107. Bird GL, Smith H, Portmann B, et al. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. QJM 1989;73:895-902
108. Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. QJM 1989;73:911-917
109. Pinto PC, Hu E, Bernstein-Singer M, et al. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990;65:878-884
110. Carman WF, Korula J, Wallace L, et al. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995;345:1406-1407
111. Wong GC, Tan P, Goh YT, et al. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Ann Acad Med Singapore 1996;25:500-503
112. Steinberg JL, Yeo W, Zhong S, et al. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 2000;60:249-255
113. Onwubalili JK. Fulminant hepatic failure in nephrotic syndrome related to withdrawal of immunosuppressive therapy. Postgrad Med J 1988;64:325-327
114. Duclos-Vallee JC, Laurent-Puig P, Loriot MA, et al. Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment. J Hepatol 1994;21:1152
115. Flowers MA, Heathcote J, Wanless IR, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990;112:381-382
116. Ito S, Nakazono K, Murasawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001;44:339-342
117. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002;99:2324-2330
118. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-709
119. Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002;36:1246-1252
120. Levin S, Leibowitz E, Torten J, Hahn T. Interferon treatment in acute progressive and fulminant hepatitis. Isr J Med Sci 1989;25:364-372
121. Rakela J, Mosley JW, Edwards VM, et al. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. Dig Dis Sci 1991;36:1223-1228
122. Trey C, Davidson C. The management of fulminant hepatic failure. In: Shaffer F, Popper H, eds. Progress in Liver Disease, Vol. 3. New York: Grune & Stratton; 1970:282-290
123. Chapman RW, Forman D, Peto R, Smallwood R. Liver transplantation for acute hepatic failure. Lancet 1990;335:32-35
124. Iwatsuki S, Steiber AC, Marsh JW, et al. Liver transplantation for fulminant hepatic failure. Transplant Proc 1989;21:2431-2434
125. Vickers C, Neuberger J, Buckels J, McMaster P, Elias E. Transplantation of liver in adults and children with fulminant hepatic failure. J Hepatol 1988;7:143-150
126. Bismuth H, Samuel D, Castaing D, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. Ann Surg 1995;222:109-119
127. Lo CM, Fan ST, Liu CL, et al. Ten-year experience with liver transplantation at Queen Mary Hospital: retrospective study. Hong Kong Med J 2002;8:240-244
128. Uemoto S, Inomata Y, Sakurai T, et al. Living donor liver transplantation for fulminant hepatic failure. Transplantation 2000;70:152-157
129. Lo CM, Fan ST, Liu CL, et al. Applicability of living donor liver transplantation to high-urgency patients. Transplantation 1999;67:73-77
130. Wang SH, Chen CL, Chen YS, et al. Living donor liver transplantation: the Kaohsiung experience. Transplant Proc 2000;32:2137-2138
131. Wai CT, Lo SK, Lee KH, et al. Ten years of experience of liver transplantation in Singapore. Transplant Proc 2000;32:2139
132. Lee SG, Park KM, Hwang S, et al. Adult-to-adult living donor liver transplantation at the Asian Medical Center, Korea. Asian J Surg 2002;25:277-284
133. Kawasaki S, Makuuchi M, Matsunami H, et al. Living related liver transplantation in adults. Ann Surg 1998;227:269-274
134. Lo CM, Fan ST, Chan JKF, et al. Minimum GV for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. Transplantation 1996;62:696-698
135. Kawasaki S, Makuuchi M, Matsunami H, et al. Preoperative measurement of segmental liver volume of donors for living related liver transplantation. Hepatology 1993;18:1115-1120
136. Williams R, Alisa A, Karani J, et al. Living related adult-to-adult liver transplantation: meeting the donor shortage. Antiviral Res 2001;52:217-223
137. Fan ST, Lo CM, Liu CL. Technical refinement in adult-to-adult living donor liver transplantation using right lobe graft. Ann Surg 2000;231:126-131
138. Fan ST, Lo CM, Liu CL, et al. Safety of donors in live donor liver transplantation using right lobe grafts. Arch Surg 2000;135:336-340
139. Liu CL, Fan ST, Lo CM, et al. Right-lobe live donor liver transplantation improves survival of patients with acute liver failure. Br J Surg 2002;89:317-322
140. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-626
141. Fang JW, Tung FY, Davis GL, et al. Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus precore mutant. Gastroenterology 1993;105:901-904
142. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847
143. Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 2000;32:1189-1195
144. Lo CM, Fung JT, Lau GK, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003;37:36-43
145. Ilan Y, Nagler A, Adler R, et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 1993;18:246-252
146. Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol 1995;23:98-101
147. Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001;13:359-361
148. Bienzle U, Gunther M, Neuhaus R, Neuhaus P. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl 2002;8:562-564
149. Ben-Ari Z, Daudi N, Klein A, et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003;98:151-159
150. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134
151. Wai CT, Lim SG, Tan KC. Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 2000;47:741
152. Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000;46:107-113